Search - tctmd.com

Displaying 281 - 300 of 857

Sort: Relevancy | Date

Presentation TCT 2015

Access Alternatives in Long SFA Disease

Presenter: Hans Krankenberg, Lindsay S. Machan, Andrej Schmidt

October 11, 2015

Presentation TCT 2015

Use of a Novel Reentry Device for a Peripheral CTO

Presenter: Mirvat Alasnag, Habib Gamra, Abdullah Shehab

October 11, 2015

Presentation TCT 2015

OCT-Guided CTO Crossing and Atherectomy: Are There Advantages of Image-Guided Intervention?

Presenter: Hans Krankenberg, Lindsay S. Machan, Roger Gammon

October 11, 2015

Presentation TCT 2015

Has the TASC Classification Scheme Been Made Obsolete by Todays Antiproliferative Therapeutics?

Presenter: Hans Krankenberg, Lindsay S. Machan

October 11, 2015

Presentation TCT 2015

Lithoplasty in Calcified SFA Lesions: Update on Outcomes and Future Trials

Presenter: Prakash Krishnan, Mahmood K. Razavi, Todd J. Brinton

October 11, 2015

Presentation TCT 2015

Debulking in the Antiproliferative Era: Which Patient Is Most Likely to Benefit?

Presenter: Prakash Krishnan, Mahmood K. Razavi, Lawrence A. Garcia

October 11, 2015

Presentation TCT 2015

A Master Class in Atherectomy: Choices, Strategies, and Execution

Presenter: Prakash Krishnan, Mahmood K. Razavi

October 11, 2015

Presentation TCT 2015

Biomimetic Stents: Rationale and Current Clinical Results

Presenter: Prakash Krishnan, Mahmood K. Razavi, Eric J. Dippel

October 11, 2015

Presentation TCT 2015

Adventitial Injection Therapy for Restenosis: Rationale and Clinical Results to Date

Presenter: Prakash Krishnan, Mahmood K. Razavi, Christopher D. Owens

October 11, 2015

Presentation TCT 2015

Update on Bioresorbable Scaffolds for PAD

Presenter: Prakash Krishnan, Mahmood K. Razavi

October 11, 2015

Presentation TCT 2015

Evolving Endovascular Treatment Strategies for Femoral-Popliteal Disease in a DES and DCB World

Presenter: Gary M. Ansel, Michael R. Jaff

October 11, 2015

Presentation TCT 2015

Review and Perspectives of the Global Registry Data for Antiproliferative Therapies

Presenter: Gary M. Ansel, Michael R. Jaff, John R. Laird Jr

October 11, 2015

Presentation TCT 2015

Review of Multicenter, Randomized Outcomes Data of Antiproliferative Therapies: Zilver PTX, LEVANT II, In.PACT SFA, and DEFINITIVE AR

Presenter: Gary M. Ansel, Michael R. Jaff, Ravish Sachar

October 11, 2015

Presentation TCT 2015

Peering Through the Veil: Outcomes Reporting in SFA Intervention Decoded

Presenter: Gary M. Ansel, Michael R. Jaff, William A. Gray

October 11, 2015

Presentation TCT 2015

Everything You Wanted to Know About Endovascular Radiation Hazards but Were Afraid to Ask

Presenter: Gary M. Ansel, Michael R. Jaff, Lindsay S. Machan

October 11, 2015

Presentation TCT 2015

PAR-1 Antagonists and P2Y12 Inhibitors: What Are the Data and the Place of These Medications in the PAD Population (for Secondary Cardiovascular Prevention and PAD Itself)?

Presenter: Gary M. Ansel, Michael R. Jaff, Ori Ben-Yehuda

October 11, 2015

Presentation TCT 2015

Is Peripheral Vascular Intervention Cost-effective? If So, From Whose Perspective?

Presenter: Gary M. Ansel, Michael R. Jaff

October 11, 2015

Presentation TCT 2015

Below-the-Knee Disease: Salvaging the Limb

Presenter: Julie Logan, Craig M. Walker

October 11, 2015

Presentation TCT 2015

Role of Atherectomy in Lower-Extremity Disease

Presenter: Julie Logan, Roger Gammon

October 11, 2015

Presentation TCT 2015

Do We Need to Reevaluate Our PTA Technique? Lessons Learned From Drug-Eluting Balloons

Presenter: Julie Logan, Krishna J. Rocha-Singh

October 11, 2015

Advertisement

Access Alternatives in Long SFA Disease

Use of a Novel Reentry Device for a Peripheral CTO

OCT-Guided CTO Crossing and Atherectomy: Are There Advantages of Image-Guided Intervention?

Has the TASC Classification Scheme Been Made Obsolete by Todays Antiproliferative Therapeutics?

Lithoplasty in Calcified SFA Lesions: Update on Outcomes and Future Trials

Debulking in the Antiproliferative Era: Which Patient Is Most Likely to Benefit?

A Master Class in Atherectomy: Choices, Strategies, and Execution

Biomimetic Stents: Rationale and Current Clinical Results

Adventitial Injection Therapy for Restenosis: Rationale and Clinical Results to Date

Update on Bioresorbable Scaffolds for PAD

Evolving Endovascular Treatment Strategies for Femoral-Popliteal Disease in a DES and DCB World

Review and Perspectives of the Global Registry Data for Antiproliferative Therapies

Review of Multicenter, Randomized Outcomes Data of Antiproliferative Therapies: Zilver PTX, LEVANT II, In.PACT SFA, and DEFINITIVE AR

Peering Through the Veil: Outcomes Reporting in SFA Intervention Decoded

Everything You Wanted to Know About Endovascular Radiation Hazards but Were Afraid to Ask

PAR-1 Antagonists and P2Y12 Inhibitors: What Are the Data and the Place of These Medications in the PAD Population (for Secondary Cardiovascular Prevention and PAD Itself)?

Is Peripheral Vascular Intervention Cost-effective? If So, From Whose Perspective?

Below-the-Knee Disease: Salvaging the Limb

Role of Atherectomy in Lower-Extremity Disease

Do We Need to Reevaluate Our PTA Technique? Lessons Learned From Drug-Eluting Balloons

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content